ArticleIndian journal of gastroenterology : official journal of the Indian Society of Gastroenterology2026
Urinary lipoarabinomannan: A novel diagnostic tool for distinguishing gastrointestinal tuberculosis from Crohn's disease.
Article in Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe differentiation between gastrointestinal tuberculosis (GITB) and Crohn's disease (CD) is challenging. Detection of urinary lipoarabinomannan (LAM), a glycolipid component of the Mycobacterium tuberculosis cell wall, has shown potential as a non-invasive diagnostic marker for tuberculosis.
objectiveWe evaluated the diagnostic accuracy of urinary LAM in distinguishing GITB from CD.
methodsThis prospective study included patients diagnosed with GITB, CD or those with indeterminate conditions (January 2021 to April 2022). Comprehensive clinical evaluations, laboratory investigations, computed tomography (CT) enterography, colonoscopy and histopathological analyses were performed. First morning midstream urine samples were collected and analyzed using TB LAM antigen kit. The analytical team was blinded from the clinical data. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and overall diagnostic accuracy of urinary LAM were determined.
resultsOf 98 patients, 36 were diagnosed with GITB and 62 with CD. Urinary LAM was positive in nine out of 36 GITB patients, yielding a sensitivity of 25% (95% C.I. 12.12-42.20%) and a PPV of 100% (95% C.I. 66.37-100.00%). None of the CD patients tested positive for urinary LAM, resulting in a specificity of 100% (95% C.I. 94.22-100.00%) and NPV of 69.66% (95% C.I. 65.54-73.50%). Overall diagnostic accuracy of urinary LAM in differentiating GITB from CD was 72.45% (95% C.I. 62.54-80.99%). Notably, the addition of urinary LAM testing to the existing diagnostic criteria improved the accurate identification of GITB from 44% to 55.6%.
conclusionUrinary LAM testing exhibits high specificity and PPV, making it a significant adjunct in the diagnostic process for GITB.
Indexed as
Identifiers
40533713What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.